Impact of Glucose-Lowering Agents on the Risk of Cancer in Type 2 Diabetic Patients. The Barcelona Case-Control Study

Simó, Rafael; Plana‐Ripoll, Oleguer; Puente, Diana; Morros, Rosa; Mundet, Xavier; Vilca, Luz María; Hernández, Cristina; Fuentes, Inmaculada; Procupet, Adriana; Tabernero, Josep; Violán, Concepción

doi:10.1371/journal.pone.0079968

Cited by 34 publications

(39 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 and Supplementary Fig. 2) (5,8,(14)(15)(16)(17)(19)(20)(21)23,25,26,28). Four of 13 studies reported an association of insulin glargine and breast cancer (8,19,21,24).…”

Section: Study Characteristics and Effect Estimatesmentioning

confidence: 99%

“…1). Following our inclusion criteria, 16 cohort and 3 case-control studies were included in this systematic review (5)(6)(7)(8)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). All studies evaluated insulin glargine, with four studies also investigating insulin detemir (15,17,25,28).…”

Section: Study Selectionmentioning

confidence: 99%

“…The mean or median durations of follow-up and age ranged from 0.9 to 7.0 years and from 52.3 to 77.4 years, respectively. Thirteen studies examined ever use of long-acting insulin analogs, which was defined as at least one prescription, compared with nonuse, other, human, or NPH insulin (5)(6)(7)(8)14,16,18,19,21,23,(25)(26)(27). One study examined duration of time since starting long-acting insulin analogs, and one examined mean daily dose (22,28).…”

Section: Study Characteristics and Effect Estimatesmentioning

confidence: 99%

“…However, residual confounding may have resulted due to the presence of unmeasured confounders. HbA 1c and diabetes duration were not accounted for in 15 of the 19 studies, resulting in likely residual confounding (7,8,(14)(15)(16)(17)(18)(20)(21)(22)(23)(24)(25)(26)28). In addition, residual confounding may have occurred in all 19 studies because none of these studies adjusted for time-dependent covariates, such as the addition of short-acting insulins or other antidiabetic medication (e.g., metformin), at all or appropriately (e.g., used a marginal structural model and inverse probability weighting to adjust for time-dependent confounders in the causal pathway).…”

Section: Residual Confoundingmentioning

confidence: 99%

“…These studies raised important concerns but were also criticized for important methodological shortcomings (9)(10)(11)(12)(13). Since then, several observational studies assessing the association between longacting insulin analogs and cancer have been published but yielded inconsistent findings (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). Such discrepancies may be due to methodological limitations, including inadequate durations of followup between insulin initiation and cancer incidence, protopathic bias, detection bias, the inclusion of prevalent users, and time-related biases such as immortal time bias, time-window bias, and time-lag bias (29).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies

Filion

Azoulay

et al. 2016

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVEObservational studies examining the association between long-acting insulin analogs and cancer incidence have produced inconsistent results. We conducted a systematic review of these studies, focusing on their methodological strengths and weaknesses. RESEARCH DESIGN AND METHODSWe systematically searched MEDLINE and EMBASE from 2000 to 2014 to identify all observational studies evaluating the relationship between the long-acting insulin analogs and the risk of any and site-specific cancers (breast, colorectal, prostate). We included cohort and case-control studies published in English on insulin glargine and detemir and any cancer incidence among patients with type 1 or 2 diabetes. The methodological assessment involved the inclusion of prevalent users, inclusion of lag periods, time-related biases, and duration of follow-up between insulin initiation and cancer incidence. RESULTSA total of 16 cohort and 3 case-control studies met our inclusion criteria. All studies evaluated insulin glargine, and four studies also examined insulin detemir. Follow-up ranged from 0.9 to 7.0 years. Thirteen of 15 studies reported no association between insulin glargine and detemir and any cancer. Four of 13 studies reported an increased risk of breast cancer with insulin glargine. In the quality assessment, 7 studies included prevalent users, 11 did not consider a lag period, 6 had time-related biases, and 16 had short (<5 years) follow-up. CONCLUSIONSThe observational studies examining the risk of cancer associated with long-acting insulin analogs have important methodological shortcomings that limit the conclusions that can be drawn. Thus, uncertainty remains, particularly for breast cancer risk.NPH insulin has been the mainstay treatment for type 1 diabetes and advanced type 2 diabetes since the 1950s. However, this insulin is associated with an increased risk of nocturnal hypoglycemia, and its relatively short half-life requires frequent administration (1,2). Consequently, structurally modified insulins, known as longacting insulin analogs (glargine and detemir), were developed in the 1990s to circumvent these limitations. However, there are concerns that long-acting insulin

show abstract

“…1 and Supplementary Fig. 2) (5,8,(14)(15)(16)(17)(19)(20)(21)23,25,26,28). Four of 13 studies reported an association of insulin glargine and breast cancer (8,19,21,24).…”

Section: Study Characteristics and Effect Estimatesmentioning

confidence: 99%